Statement: Patients in the primary trial and the secondary trial will take Herceptin¬¨¬© (trastuzumab) or paclitaxel intravenously.
Primary_evidence: INTERVENTION 1:    Diagnostic (18F-FLT)   Patients undergo 18F-FLT PET/CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery, FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy.   Fluorothymidine F-18: Undergo 18F-FLT PET/CT   Positron Emission Tomography: Undergo 18F-FLT PET/CT   Computed Tomography: Undergo 18F-FLT PET/CT   Laboratory Biomarker Analysis: Correlative studies
Secondary_evidence: INTERVENTION 1:    Herceptin© + Taxane   Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.   Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal . INTERVENTION 2:    MYL-1401O Trastuzumab + Taxane   Part 1:Myl 1401OTrastuzumab Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.   Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Myl 1401O( Mylan Trastuzumab) alone once every 3 weeks until DP or subject withdrawal.